Navigation Links
Senesco Technologies Reports Third Quarter Fiscal 2008 Financial Results

NEW BRUNSWICK, N.J., May 16 /PRNewswire-FirstCall/ -- Senesco Technologies, Inc. ("Senesco" or the "Company") (Amex: SNT) today reported financial results for the three months ended March 31, 2008.

Net loss for the three month period ended March 31, 2008 was $2.0 million, or $0.12 per share, compared with a net loss of $0.8 million, or $0.05 per share, for the three month period ended March 31, 2007. This increase in net loss was primarily the result of an increase of $0.8 million in expenses associated with the outstanding convertible notes that were issued during the current fiscal year, and an increase in operating expenses.

Quarterly and Recent Highlights

-- Senesco regained compliance with AMEX's continued listing requirements.

-- Preclinical pancreatic islet cell research that was funded by the

Company was presented at two important industry conferences, the

Keystone Islet and Beta Cell Symposium, and the Upper Midwest Islet

Club's Annual Meeting. Using a small interfering RNA (siRNA) against

Senesco's Factor 5A technology, the data showed what Senesco believes

to be a variety of promising results regarding delivery of the

technology, as well as islet protection and function.

-- The Company announced the results of preclinical animal studies focused

on multiple myeloma. In the studies, mice were injected subcutaneously

with human multiple myeloma cancer cells to form myeloma tumors in

their flanks. Treated mice were injected intratumorally with Factor 5A

therapy encapsulated in nanoparticles, while control mice received a

nanoparticle without the Factor 5A therapy. One of the dosing regimens

showed evidence of significant tumor regression relative to the

untreated control mice, while the other showed a diminished rate of

tumor growth along with some regression.

-- Initial field trials conducted with ArborGen, LLC over a three-year

period in certain species of trees have concluded and the trees have

been harvested for wood quality assessment. Preliminary data from the

field trials show significantly enhanced growth rates in some of the

trees relative to controls. The Company and ArborGen have selected

promising genetic lines which are now being prepared for additional

field trials.

Bruce Galton, President and Chief Executive Officer of the Company, said, "We continue to progress our human health programs and believe we have positive preclinical results in our multiple myeloma studies and pancreatic islet cell research. Senesco is working closely with our contract research organization in evaluating materials and planning the work ahead for our multiple myeloma program. In addition, our agricultural licensees have initiated research with our technology in crops such as corn, soy, rice, canola and cotton. We continue banana field trials with our joint venture partner, Rahan Meristem. Our technology provides a very broad platform of applications for human health in oncology and inflammatory diseases and across a variety of food and non-food agricultural crops."

Revenue of $79,167 for the three-month period ended March 31, 2008 consisted of milestone payments and the amortized portion of previous milestone payments received in connection with certain license agreements. During the three-month period ended March 31, 2007, revenue of $6,250 consisted of the amortized portion of previous milestone payments received in connection with certain development and license agreements.

Research and development expenses during the three-month period ended March 31, 2008 were $474,176, compared with $314,294 during the three-month period ended March 31, 2007. This increase resulted from an expansion of Senesco's human health programs, including the Company's cancer research program, and an unfavorable exchange rate variance in connection with Senesco's research agreement at the University of Waterloo. The Company expects research and development expenses to continue to increase as it expands its research activities, particularly in the area of human health.

General and administrative expenses were $876,966 for the three-month period ended March 31, 2008, compared with $514,189 during the three-month period ended March 31, 2007. This increase was primarily due to a $458,000 increase in stock-based compensation, which includes the Black-Scholes value of $384,000 of warrants extended and repriced in connection with an amendment to a financial advisory agreement entered into February 14, 2008, the amortized portion of the compensation charge in connection with our short-term stock incentive plan and the amortized portion of the Black-Scholes value of options and warrants previously granted to directors, employees and consultants. This was partially offset by a $79,000 decrease in depreciation and amortization.

At March 31, 2008, Senesco had cash, cash equivalents and investments of $4,549,233. With the remaining potential gross proceeds of $3 million of the Company's previously announced $10 million financing, Senesco should be able to operate according to the Company's current business plan for the next 18 months. The receipt of the remaining $3 million of proceeds is dependent upon entering into certain supply agreements with third party manufacturers. If Senesco does not meet all or some of the foregoing funding milestones, then the current $4.5 million is sufficient for the next 12 months.

About Senesco Technologies, Inc.

Senesco Technologies, Inc. is a U.S. biotechnology company, headquartered in New Brunswick, NJ. Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if the technology is applicable in human medicine. Accelerating apoptosis may have applications to development of cancer treatments. Delaying apoptosis may have applications to certain diseases inflammatory and ischemic diseases. Senesco takes its name from the scientific term for the aging of plant cells: senescence. Delaying cell breakdown in plants extends freshness after harvesting, while increasing crop yields, plant size and resistance to environmental stress. The Company believes that its technology can be used to develop superior strains of crops without any modification other than delaying natural plant senescence. Senesco has partnered with leading-edge companies engaged in agricultural biotechnology and earns research and development fees for applying its gene-regulating platform technology to enhance its partners' products.

Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the development of the Company's gene technology; the approval of the Company's patent applications; the successful implementation of the Company's research and development programs and joint ventures; the success of the Company's license agreements; the acceptance by the market of the Company's products; success of the Company's preliminary studies and preclinical research; competition and the timing of projects and trends in future operating performance, the Company's ability to meet its funding milestones under its financing transaction, the Company's ability to comply with the continued listing standards of the AMEX, as well as other factors expressed from time to time in the Company's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Company Contact: Investor Relations Contact:

Senesco Technologies, Inc. FD

Joel Brooks Brian Ritchie

Chief Financial Officer 212-850-5600

(732) 296-8400

(tables to follow)





For the For the For the

Three Three Nine

Months Months Months

Ended Ended Ended

March 31, March 31, March 31,

2008 2007 2008

Revenue $79,167 $6,250 $456,667

Operating Expenses:

General and

administrative 876,966 514,189 1,851,876

Research and development 474,176 314,294 1,219,325

Total Operating Expenses 1,351,142 828,483 3,071,201

Loss From Operations (1,271,975) (822,233) (2,614,534)

Sale of state income

tax loss, net -- -- --

Other noncash -- -- --

income 43,907 20,916 76,013

Interest income, net (628,626) -- (927,054)

Amortization of debt

discount and financing


Interest expense on

convertible notes (187,473) -- (255,309)

Net Loss $(2,044,167) $(801,317) $(3,720,884)

Basic and Diluted Net

Loss Per Common Share $(0.12) $(0.05) $(0.21)

Basic and Diluted

Weighted Average

Number of Common

Shares Outstanding 17,583,461 17,473,694 17,510,410






For the Inception

Nine on July 1,

Months 1998

Ended through

March 31, March 31,

2007 2008

Revenue $268,750 $1,175,000

Operating Expenses:

General and administrative 2,001,068 21,286,069

Research and development 863,037 9,412,494

Total Operating Expenses 2,864,105 30,698,563

Loss From Operations $(2,595,355) $(29,523,563)

Sale of state income tax loss, net -- 586,442

Other noncash -- 321,259

income 57,936 455,801

Interest income, net -- (927,054)

Amortization of debt discount

and financing costs

Interest expense on convertible

notes -- (255,309)

Net Loss $(2,537,419) $(29,342,424)

Basic and Diluted Net Loss Per

Common Share $(0.15)

Basic and Diluted Weighted

Average Number of Common

Shares Outstanding 16,732,003




March 31, June 30,

2008 2007




Cash and cash equivalents $4,049,233 $408,061

Short-term investments 500,000 250,000

Prepaid expenses and other current assets 57,695 104,526

Total Current Assets 4,606,928 762,587

Property and equipment, net 6,880 7,526

Intangibles, net 3,032,449 2,544,447

Deferred financing costs 729,029 --

Security deposit 7,187 7,187

TOTAL ASSETS $8,382,473 $3,321,747



Accounts payable $168,525 $109,258

Accrued expenses 509,619 377,359

Deferred revenue -- 16,667

Total Current Liabilities 678,144 503,284

Convertible note, net of discount 819,525 --

Grant payable 99,728 99,728

Other liability 24,595 29,196

TOTAL LIABILITIES 1,621,992 632,208


Preferred stock, $0.01 par value; authorized


no shares issued -- --

Common stock, $0.01 par value; authorized

100,000,000 shares, 177,283 174,737

issued and outstanding 17,728,314 and

17,473,694, respectively

Capital in excess of par 35,925,622 28,136,342

Deficit accumulated during the development

stage (29,342,424) (25,621,540)

TOTAL STOCKHOLDERS' EQUITY 6,760,481 2,689,539


SOURCE Senesco Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Senesco Technologies Regains Compliance With Amexs Continued Listing Requirements
2. Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results
3. Senesco Technologies Reports on Results of Preclinical Multiple Myeloma Studies
4. Senesco Technologies Closes on Additional $4.0 Million of Previously Announced Financing
5. Adnavance Technologies Inc. Appoints Christian P. Valcke, Ph.D., to Its Scientific Advisory Board
6. Sturgeon and Caviar From Aquaculture: United Food Technologies AG Hands Over Turnkey Plant
7. Palatin Technologies Announces New Strategic Objectives and Reports Third Quarter 2008 Financial Results
8. Veran Medical Technologies Secures $4.75M in First Institutional Funding
9. Neurobiological Technologies Reports Third Quarter Financial Results
10. InSet Technologies Appoints Jon Tremmel to its Board of Directors
11. Applied Isotope Technologies will Exclusively Supply Biochemimarker(TM) Discovery Products for a Unique Pilot Study on Autism
Post Your Comments:
(Date:10/12/2017)... ... October 12, 2017 , ... They call it ... biological network, a depiction of a system of linkages and connections so complex ... associate professor of computer science at Worcester Polytechnic Institute (WPI) and director of ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... of a United States multicenter, prospective clinical study that demonstrates the accuracy ... test capable of identifying clinically significant acute bacterial and viral respiratory tract ...
(Date:10/12/2017)... (PRWEB) , ... October 12, ... ... ) has launched Rosalind™, the first-ever genomics analysis platform specifically designed for ... complexity. Named in honor of pioneering researcher Rosalind Franklin, who made a ...
(Date:10/11/2017)... ... ... a basic first aid supply for any work environment, but most personal eye wash can ... a dangerous substance enters both eyes? It’s one less decision, and likely quicker response time ... , “Whether its dirt and debris, or an acid or alkali, getting anything in your ...
Breaking Biology Technology:
(Date:5/23/2017)... robotic gym for the rehabilitation and functional motor sense evaluation of lower ... . The first 30 robots will be available from June in ... The technology was developed and patented at the IIT laboratories and has ... to a 10 million euro investment from entrepreneur Sergio Dompè. ... ...
(Date:4/19/2017)... York , April 19, 2017 ... as its vendor landscape is marked by the presence ... market is however held by five major players - ... Together these companies accounted for nearly 61% of the ... the leading companies in the global military biometrics market ...
(Date:4/11/2017)... GARDENS, Fla. , April 11, 2017 /PRNewswire/ ... management and secure authentication solutions, today announced that ... by Intelligence Advanced Research Projects Activity (IARPA) to ... IARPA,s Thor program. "Innovation has been ... and IARPA,s Thor program will allow us to ...
Breaking Biology News(10 mins):